A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

NCT07633470 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: Zunveyl®

Sponsor

Alpha Cognition, Inc